On Nov. 15, 2019, the Knight Cancer Institute's Precision Oncology program, led by Dr. Gordon Mills, M.D., Ph.D., invited four speakers to discuss their work on determining and testing cancer treatments using the lowest possible dose of therapeutic drugs.
Dr. Mills along with speakers Drs. Alexander Anderson, Ph.D. (Moffitt Cancer Center), Senthil Muthuswamy, Ph.D. (Beth Israel Deaconess Medical Center Harvard Medical School), Alex Gaither, Ph.D. (LG Chem Life Sciences Innovation Center, Inc.), and Jeremy Goecks, Ph.D. (OHSU), joined the Nov. 15 "Durable Responses with Acceptable Toxicity" symposium to discuss their work developing cutting-edge techniques to determine what kinds of patients will respond to which treatments and when to stop and start treatments.
This is a vital area of study because traditional cancer treatments involve giving patients the highest possible dose of a drug or multiple drugs to kill off cancer cells. However, this standard of treatment causes cancers cells to become resistant to therapy quickly. With lower doses of medication, patients save money and can be spared the potential toxicity that comes at high doses.
Read more about our presenters: